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INTRODUCTION
The malignant tumors in the upper respiratory tract and the upper
digestive organs have some unique structural, pathological and
dynamic characteristics in terms of their developmental process.
Head and neck cancers are mostly squamous cell carcinomas and
they are divided into well-differentiated, moderately-differenti-
ated and poorly-differentiated lesions (1). Squamous cell carci-
noma of the larynx has high morbidity and mortality rates. Its
treatment has recently become somewhat better as the medical
treatments have improved and new therapies have been devel-
oped, but the index used to determine the proper therapeutic me-
thods and to judge the prognosis of this malady is still not suffi-
cient. Thus, various studies are currently being conducted to deter-
mine the malignancy of this type of tumor. If researchers can find
a factor to objectively appraise the biological characteristics of a
cancer from the samples of tumor tissues, for example, appraising
the malignancy of the cancer cells, then this will be a more releiable
prognostic factor than the clinical stage, which is the factor that
has been used for this in the past (2).
Galectin-8 is one of the galectins, which are a group of mam-
mal lectins. It is a 34 kDa protein and it is composed of two car-
bohydrate-recognition domains (CRDs). It gets coupled by dif-
ferent lengths of “link peptide” (3, 4). The same as other galectins,
it is secreted as a secretory protein to become a matrix protein
that gets connected with some selective parts of the integrins on
the surface of a cell or it becomes a matrix protein that forms a
group of proteins that play a role for encouraging cell adhesion
in a fashion similar to fibronectin (5). The existing studies have
shown that galectin-8 has a positive relation with some human
cancers, and especially with prostatic carcinoma (6).
Recently, the usefulness of galectin-8 has been researched, but
its roles in the head and neck cancers has not been studied yet.
Therefore, this paper intends to examine the correlations between
the expression pattern of galectin-8 in squamous cell carcinoma
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Original Articleof larynx and T-stage of the tumor, metastasis to the lymph node,
clinical stage, and histopathologic differentiation. And based on
the examination, it will study the possibility of galectin-8 as a
prognostic factor. For this study, immunohistochemical staining
will be peformed on galectin-8. 
MATERIALS AND METHODS
Patients
Seventy-seven cases of squamous cell carcinoma of larynx that
were clearly diagnosed via biopsy from 1993 to 2007 were used
for this study. They were classified by the differentiation of the
tumor and the stage of the disease. The patients were 29-81 yr
old (average age: 63); 72 of them were males (93.5%) and 5 were
females (6.5%). In terms of the histopathologic differentiation,
23 cases were well-differentiated, 17 cases were moderately-dif-
ferentiated, and 5 were poorly-differentiated. It was impossible
to confirm the histologic differentiation of 32 cases, and these were
excluded from the statistical analysis of histologic differentiation.
The T-stage and the clinical stage, according to the presence of
cervical lymph node metastasis, were classified by the American
Joint Committee on Cancer (AJC) classification (2002). Based
on the T-stage, 16 cases were T1, 20 cases were T2, 26 cases were
T3, and 15 cases were T4. Based on the N-stage, 55 cases were
N0, 10 cases were N1, 10 cases were N2, and 2 cases were N3.
Based on the clinical stage, 14 cases were 1st stage, 16 cases were
2nd stage, 23 cases were 3rd stage, and 24 cases were 4th stage.
The biopsy report and medical treatment records of each patient
were reviewed to determine the TNM stage and the histologic
differentiation. 
Reagent
Galectin-8 (H-80, SC-28254) manufactured by Santa Cruz Bio-
technology (Santa Cruz, CA, USA) was used as the primary
antibody for the immunohistochemical tests, and a Labeled
Streptavidin Biotin (LSAB) kit and diaminobenzoic acid (DAB)
kit made by Dako (Glostrup, Denmark) were used as the sec-
ondary antibody and the color former, respectively. Counter-
staining was performed with Mayer’s hematoxylin and a uni-
versal mount made by Research Genetics (Huntsville, AL, USA)
was used for sealing.
Optical microscopic study 
The lesions of the larynx were re-examined by using the slide files
of the tissues at the laboratory, and the presence of cancer infil-
tration was re-checked. The representative parts suitable for the
purposes of this research were chosen and then slides were made
for the immunohistochemical tests. 
Immunohistochemical study
Paraffin embedded tissues that had been fixed in 10% neutral
buffered formalin were cut to 4 μ m thickness and then they were
attached to X-tra
TM slides (Surgipath, Richmond, IL, USA). They
were deparaffined by using xylene and then they were treated
with 90% non-aqueous alcohol and 75% and 50% ethanol for 2
min, respectively. They were then stained by the LSAB method.
For the recovery of antigen, the slides were put into citrate buffered
solution (10 mM, pH 6.0) and this was boiled in a microwave for
15 min. They were left at room temperature for 20 min and next
washed with 50 mM Tris buffered solution (TBS, pH 7.5). In order
to suppress the activation of intrinsic peroxidase in the tissue sec-
tions, the slides were treated with 0.3% hydrogen peroxide-me-
thanol for 10 min and then they were washed with distilled water.
They were reacted with a growth blocking antibody at room te-
mperature for 10 min and then they were reacted with the prima-
ry antibody galectin-8 (dilution-1:400) for 1 hr. They were washed
with Tris buffered solution and then reacted with the secondary
antibody containing biotin at room temperature for 10 min with
using LSAB kits. After this they were washed with tryptic soy broth
(TSB) and made to react with peroxidase-coupled streptavidin
solution for 10 min. They were washed again with Tris buffered
solution and then reacted with diaminobenzidine (DAB). Counter-
staining was performed with Mayer’s hematoxylin and universal
mount was used for sealing. As a negative control group, Tris bu-
ffered solution was used instead of primary antibody.
Interpretation of the immunohistochemical staining
The results of the immunohistochemical stainings were read by
a pathologist who was without knowledge of the clinical infor-
mation. The cases for which galectin-8 was stained on the cyto-
plasm of a cancer cell in the form of brown granules were judged
positive and we compared the percentages of the positively stained
cancer cells out of more than 1,000 cancer cells within the tumor
region. The case that the cancer cells were stained less than 1%
in 100 magnified fields was scored at 0. The case that cancer cells
were stained less than 10% was scored as 1 point, the case that
the cancer cells were stained 11-50% was scored as 2 points and
3 points were given when more than 51% of the cancer cells were
stained. 
Depending on the strength of staining, the samples were clas-
sified into negative (0 point), weak positive (1 point), moderate
positive (2 points) and strong positive (3 points). If the points for
the strength of staining and the points for the distribution were
added up as 0-2 points, then this was classified as category I. If
they are added up as 3-4 points, then this was classified as cate-
gory II and if they are added up as 5-6 points, then this was clas-
sified as category III. Category I was judged as negative while ca-
tegories II and III were judged as positive (7).
Statistical analysis 
Correlations between the relative extent of galectin-8 in the lesions
of squamous cell carcinoma of the larynx and the prognostic fac-
tors (the size of the original cancer, metastasis to the cervical ly-
14 Clinical and Experimental Otorhinolaryngology  Vol. 2, No. 1: 13-19, March 2009mph node, the clinical stage and the histopathological differen-
tiation) were tested by use of Chi-square tests. P<0.05 was regard-
ed statistically significant.
RESULTS
The clinical and histologic results 
A total of 77 tissue samples of squamous cell carcinoma of the
larynx were classified by clinical stage: 30 cases were early can-
cer (Stages I and II) and 47 cases were advanced cancer (Stages
III and IV). Based on the T-stage, 37 cases were classified as early
stage (T-stages 1 and 2) and 41 cases were advanced stage (T-
stages 3 and 4). Twenty-two cases were classified as a group show-
ing metastasis to the cervical lymph nodes (N ≥1) and 55 cases
were classified as the group showing no metastasis to the cervi-
cal lymph nodes (N0). Depending on the histologic differentia-
tion, the cases of squamous cell carcinoma were classified as 23
cases of well-differentiated tumor, 17 cases of moderately-differ-
entiated tumor and 5 cases of poorly-differentiated tumor. 32 cases
couldn’t be classified (Table 1).
Immunohistochemical expression of galectin-8
Among the 77 samples, there was no case (0%) showing that
cancer cells were stained less than 1% at 100 magnifications. There
was 1 case (1.3%) showing that cancer cells were stained less
than 10%. 18 cases (23.4%) showed 11-50% staining while 58
cases (75.3%) showed more than 51% staining. Based on the
strength of the staining, 0 cases (0%) were negative, 11 cases
(14.2%) were weakly positive, 30 cases (39.0%) were moder-
ately positive and 33 cases (42.8%) were strongly positive. Ca-
tegory I, whose total points for the strength of staining and the
points for distribution were 0-2, had 1 case (1.3%). Category II
(3-4 points) had 21 cases (27.3%) and category III (5-6 points)
had 55 cases (71.4%) (Table 2).
Immunohistochemical staining showed a strong reaction around
the part of the squamous cell carcinoma of the larynx, and it was
especially observed to be stronger on the part where the cancer
cells invaded the stroma (Fig. 1). Compared with the normal tis-
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Characteristics N (%)
Table 1. The clinical, epidemiologic and histologic characteristics
of 77 patients with laryngeal squamous cell carcinoma (%)
Number of patients 77
Age (yr)
Mean 63
Range 29-81
<0 25 (32.5)
≥0 52 (67.5)
Gender
Male 72 (93.5)
Female 5 (6.5)
Tumor stage
Early (1, 2) 36 (46.8)
11 6
22 0
Advanced (3, 4) 41 (53.2)
32 6
41 5
Lymph node metastasis
No (N0) 55 (71.4)
Yes (N≥1) 22 (28.6)
Clinical stage
Early (I, II) 30 (39.0)
I1 4
II 16
Advanced (III, IV) 47 (61.0)
III 23
IV 24
Histopathologic differentiation 45
Well differentiated 23 (51.1)
Moderately, poorly differentiated 22 (48.9)
Alcohol
Yes 37 (48.1)
No 40 (51.9)
Smoking
Yes 59 (76.6)
No 18 (23.4)
Category I Category II  Category III Total
Table 2. The immunohistochemical staining results for galectin-8 in
laryngeal squamous cell carcinoma (%)
Galectin-8 1 (1.3) 21 (27.3) 55 (71.4) 77
Fig. 1. Immunohistochemical staining of galectin-8 in laryngeal squa-
mous cell carcinoma shows intense immunoreactivity (arrows), and
particularly in the stromal invasive region (LSAB method, counterst-
ained by Mayer’s hematoxylin, ×200).sues or the squamous epithelium with dysplasia, the expression
of galectin-8 was stronger around the cancer cells (Fig. 2).
Correlation between the expression of galectin-8 and the
tumor stage 
For the study of the positive expression of galectin-8 based on
the T-stage, T1 and T2 were classified as the early group (n=36),
and T3 and T4 were classified as the advanced group (n=41). For
the early stage group, category I had no cases, category II had 19
cases and category III had 17 cases. In the advanced group, cat-
egory I had 1 case, category II had 2 cases and category III had
38 cases, and the differences between the groups were statisti-
cally significant (P<0.05) (Table 3).
Correlation between the expression of galectin-8 and
metastasis to the cervical lymph nodes 
Based on the clinical data, the cases were divided into the group
that had no metastasis to the cervical lymph nodes (N0) (n=55)
and the group that had metastasis to the cervical lymph nodes
(N≥1) (n=22). In the group that had no metastasis to the cervi-
cal lymph nodes (N0), category I had 1 case, category II had 21
cases and category III had 33 cases. In the group that had metas-
tasis to the cervical lymph nodes (N≥1), category I had 0 case,
category II had 0 case and category III had 22 cases, and the dif-
ferences between the groups were statistically significant (P<
0.05) (Table 4).
Correlation between the expression of galectin-8 and the
clinical stage 
The cases were divided into two groups: the group with early
stages 1 and 2 (n=30) and the group with advanced stages 3 and
4 (n=47). In the early stage group, category I had 0 case, catego-
ry II had 19 cases and category III had 11 cases. In the advanced
stage group, category I had 1 case, category II had 2 cases and
category III had 44 cases, and the differences between the groups
were statistically significant (P<0.05) (Table 5).
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T-stage*
Early (T1, 2) Advanced (T3, 4)
(n=36) (n=41)
Table 3. The statistical analysis of the immunohistochemical galectin-
8 expression according to the T-stage (%)
*Statistically significant, P<0.05.
Galectin-8 Category I 0 (0.0) 1 (2.4) 1 (1.3)
Category II 19 (52.8) 2 (4.9) 21 (27.3)
Category III 17 (47.2) 38 (92.7) 55 (71.4)
Fig. 2. Immunohistochemical staining of galectin-8 in laryngeal squa-
mous cell carcinoma. A strong galectin-8 expression (arrows) is iden-
tified in the squamous cell carcinoma (lower portion) as compared
with the normal and dysplastic squamous epithelium (upper portion)
(LSAB method, counterstained by Mayer’s hematoxylin, ×200).
Nodal stage*
Negative (N0) Positive (N≥1)
(n=55) (n=22)
Table 4. The statistical analysis of the immunohistochemical galectin-
8 expression according to the nodal stage (%)
*Statistically significant, P<0.05.
Galectin-8 Category I 1 (1.8) 0 (0.0) 1 (1.3)
Category II 21 (38.2) 0 (0.0) 21 (27.3)
Category III 33 (60.0) 22 (100.0) 55 (71.4)
Clinical stage*
Early (I, II) Advanced (III, IV)
(n=30) (n=47)
Table 5. The statistical analysis of the immunohistochemical galectin-
8 expression according to the clinical stage (%)
*Statistically significant, P<0.05.
Galectin-8 Category I 0 (0.0) 1 (2.1) 1 (1.3)
Category II 19 (63.3) 2 (4.2) 21 (27.3)
Category III 11 (36.7) 44 (93.7) 55 (71.4)
WD MD+PD Total
(n=23) (n=22) (n=45)
Table 6. The statistical analysis of the immunohistochemical galec-
tin-8 expression according to the tumor’s histopathologic differen-
tiation (%)
WD: well differentiated; MD: moderately differentiated; PD: poorly differen-
tiated.
Galectin-8 Category I 0 (0.0) 1 (4.5) 1 (1.3)
Category II 5 (21.7) 5 (22.7) 10 (22.2)
Category III 18 (78.3) 16 (72.8) 34 (75.6)Correlation between the expression of galectin-8 and the
histopathological differentiation 
The cases were divided into three groups: well-differentiated (n=
23), moderately-differentiated and poorly-differentiated (n=22).
In the well-differentiated group, category I had 0 case, category
II had 5 cases and category III had 18 cases. In the moderately
and poorly-differentiated group, category I had 1 case, category
II had 5 cases and category III had 16 cases. Category III had more
cases, but this was not statistically significant (Table 6).
DISCUSSION
Squamous cell carcinoma of the larynx can be completely cured
by operations, but it can inevitably cause complications, includ-
ing dysphonia. In spite of the evolution of operative techniques,
radiotherapy and anticancer medicine, the success rate for treat-
ing squamous cell carcinoma of the larynx and the patient survival
have not been greatly improved. Under these circumstances, it
is urgent to develop new treatment methods. To do this, it is im-
portant to make treatment plans at the early stage of the cancer
and to use a prognostic factor with which a doctor can diagnose
and cure the cancer early (8).
The prognosis of squamous cell carcinoma of the larynx is de-
termined by several factors (factors of the cancer, factors of a pa-
tient and factors of treatment) (2). Among those prognostic fac-
tors, the clinical stage (a factor of the cancer) has been used most
often, but the clinical progress and the prognosis can be different
depending on tumor’s origin, the biological characteristics of the
cancer cell, and the differences in the cellular/microscopic envi-
ronment, even though the clinical stage is same. Therefore, stud-
ies have been conducted to determine the prognosis by measur-
ing the malignancy of the cancer cells (9).
Along with the rapid development of molecular biology, cell
biomarkers have been used as a variable for appraising the clin-
ical malignancy of a cancer (10). Studies on the expression of can-
cer protein by performing immunohistochemical staining are being
actively conducted, but the research on galectin-8 is not sufficient
and any studies on the head and neck cancers are especially rare.
Galectin is 31 kDa carbohydrate-coupled protein that belongs
to the beta-galactoside-binding animal protein lectin family. The
chief characteristic of this protein family is that it shares carbo-
hydrate recognition binding domains (CRDs). Depending on the
number and the structure of the CRDs, it is classified into the proto
type, the tandem repeat type and the chimera type (11, 12). At
present, a total of 14 kinds of galectin protein have been found.
The proto type has one CRD and galectin -1, -2, -5, -7, -10, and
-13 are the proto type. The tandem repeat type has two CRDs,
which includes galectin -4, -6, -8, -9, -12, and -14, and the CRDS
are connected by a hinge peptide. Galectin-3 has one CRD, which
contains a Pro-Gly-rich repeat unit, so it belongs to the chimera
type (13, 14). It is known that galectins are in epithelial cells and
immune cells and they are involved in such biological functions
as embryogenesis, cell growth, cell adhesion, cell proliferation,
apoptosis and mRNA splicing (15-17). In addition, this protein
is known to be distributed in the cytoplasm, nuclei, cell walls and
extracellular matrix, and this protein is related with tumorigen-
esis and metastasis (18). The human galectin-8 gene (LGALS8)
conforms to 33 kbp of DNA. Galectin-8 is located at chromosome
1 (1q42.11), which includes 11 exons. It encodes mRNA through
splicing of 14 different transcripts (6). This mRNA encodes 6 is-
oform proteins of galectin-8 and among them, 3 belong to the
tandem repeat galectin type, while another 3 belong to the proto
type. The proto type galectin-8 has never been isolated and it
has been hypothetically deducted from the separated transcripts
(19). Therefore, galectin-8 belongs to the subtype of the tandem
repeat type galectin. It includes 2 CRDs and they are connected
by a 32-amino acid linker (Fig. 3) (6). At the level of hexane, ga-
lectin-8 is consistent with galectin-4 with 50% homology, and at
the level of amino acids, it shows 34% homology (3, 20). How-
ever, galectin-4 and galectin-8 play similar or different roles in
the generation of cancer is not known (21). The previous stud-
ies have reported that galectin-8 is a controller of stromal cells
as is related with cell adhesion, and its function requires that both
CRDs should be activated (5, 22). This has been revealed to be
different in normal cells and cancer cells, and so galectin-8 is help-
ful for understanding the growth and differentiation of malignant
tumors (23-26).
Galectin-8 is extensively expressed in normal tissues (brain,
breast, large intestine, retina, kidney, pancreas, placenta, spleen,
testicle, uterus, blood vessel, esophagus and heart), and it is also
distributed in cancer tissues (brain, breast, large intestine, germ
cells, head and neck, kidney, muscles, ovary, pancreas, thyroid
gland, placenta, prostate, uterus, lung, stomach and esophagus
cancer) (3, 27-30). Danguy et al. (24) compared the expression
of galectin-8 by the type of an organ according to immunohis-
tochemical staining on the cancer tissues that correspond with
normal tissues. They stated that for the tissues of the large intes-
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Fig. 3. Galectin-8 encodes for a galectin with two homologous carbo-
hydrate-binding regions. A schematic structure of galectin-8 is pre-
sented. Each box represents a putative carbohydrate-binding domain,
linked by a 32 amino acid-long peptide. Also shown are selected in-
variant amino acids that are preserved in most of the galectins that
have currently been analyzed.
Schematic structure of galectin-8 isoforms
N-terminal domain Link peptide C-terminal domain
~150 32 ~130
amino amino amino
acids acids acids
~HFNPRL~VCN~W ~H~NPRL~VRN~WGtine, the pancreas, the liver, the skin and the larynx, the cancer
tissues had a lower expression of galectin-8 than did the normal
tissues; for the tissues of the breast, there was no difference be-
tween the cancer tissues and the normal tissues, and the expres-
sion of galectin-8 was increased in the cancer tissues of the lungs,
the bladder, the kidney, the prostate and the stomach. Thus, ga-
lectin-8 expression for the malignant transformation of an epithe-
lial originated tissue, immunohistochemical monitoring of galectin-
8 reveals an organ-type-dependent regulation. There is a report
that the galatin-8 expression is reduced in the laryngeal squamous
cells as compared with that of normal tissues.
In our study, we didn’t compare the extent of the galectin-8
expression between the normal larynx tissues and the tissues of
squamous cell carcinoma of the larynx, but we found an increased
expression of galectin-8 that was caused by an increase in the
malignancy of the squamous cell carcinoma of the larynx. A study
on the expression of galaction-8 in normal tissue as compared
with that in the corresponding cancer tissues needs to be conduct-
ed in the future.
Su et al. (31) have shown that the secretion and the surface
expression of galectin-8 were very high in invasive prostatic car-
cinoma, early prostatic carcinoma and prostatic carcinoma in situ,
but galactin-8 was not increased in the normal prostatic tissues
and the tissues of benign prostatic hypertrophy. Because of this
reason, galectin-8 was called Prostate Cancer Tumor Antigen-1
(PTCA-1) in the past (31). The excessive expression of galectin-
8 was observed in the cells of lung cancer, the cancer cells of the
central nervous system (astrocytoma and glioblastoma) and the
cancer cells of skin T-cell lymphoma and cholesteatoma (26, 32,
33). This excessive expression of galectin-8 seems to be a key ch-
aracteristic that is connected with the progress of some tumors.
Nagy et al. (25) studied the expression of galectin-8 in colon
cancer and they found that depending on the change in the malig-
nancy of the colon tissues, the immunohistochemical expression
of galectin-8 was remarkably decreased, and as the malignancy
of a tumor became higher, the amount of galectin-8 protein was
reduced so that the expression of galectin-8 was lower in the can-
cer tissues than that the normal tissues or the benign tissues of
the colon cancer. This result is completely opposite to the result
of this research that the expression of galectin-8 was increased
as the malignancy of the squamous cell carcinoma of larynx in-
creased. So, this suggests that the expression of galectin-8 caused
by malignancy is different according to the kind of an organ.
An immunohistochemical staining study was previously con-
ducted on the primary and secondary lung cancers of various
histologic types (29, 30). Henno et al. (29) found that galectin-8
was strongly expressed in squamous cell carcinoma of the lung,
but it was weakly expressed in adenocarcinoma and it was not
revealed at all in small-cell carcinoma. By observing the relations
between the expression of galectin-8 and the differentiation of
squamous cell carcinoma and neuroendocrine tumor, they insist-
ed that the expression of galectin-8 was related with the type of
a tumor. Through those researches, it will be possible to clarify
the same relation (the expression of galectin-8 increases with the
increased malignancy of squamous cell carcinoma of the larynx)
in other tumors. In addition, it might be possible to use galactin-
8 as a prognostic factor for various tumors, and especially squa-
mous cell carcinoma.
The difference in the expression of galectin-8 between normal
tissues and tumor tissues has recently been used as a guide for
the treatment and for selecting a preventive method for treating
squamous cell carcinoma of the lungs (19). These various experi-
ments are now being reviewed and appraised, but they show the
different potentialities of galectin-8 and further, they help us in-
crease our understanding of this protein. In addition, these exper-
iments show the possibility that galactin-8 can be used to block
tumorigenesis.
We performed immunohistochemical staining for galctin-8 on
77 cases of squamous cell carcinoma of the larynx, and the corre-
lations between the expression of galectin-8 and the tumor stage,
metastasis to the lymph nodes, the clinical stage and the histolog-
ic differentiation were examined and statistically analyzed. The
following conclusions were made.
Galectin-8 seems to be closely related to the tumorigenesis of
squamous cell carcinoma of the larynx and its malignancy, while
it also controls cell adhesion and the interactions between cells
and the stroma of the larynx during various physiological and
pathological progresses. The expression of galectin-8, depending
on the tumor stage, metastasis to the lymph nodes and then clin-
ical stage, was statistically significant enough to be used as a clin-
ical prognostic factor for squamous cell carcinoma of the larynx.
We found that the expression of galactin-8 was not statistically
related with histologic differentiation. However, more cases are
needed to confirm this and a study that focuses on comparing
the expression of galactin-8 between normal tissues and cancer
tissues needs to be done in the future to further determine the
correlation of galaction-8 with other factors. 
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